Loading…
ACRV
Acrivon Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 004890109
$2.15+6.97%Price as of Sep 22, 22:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $92.13M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.88
- ROE
- -64.63%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.93
- 52-week high
- $3.56
- 52-week low
- $1.27
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -83.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.41 | $6.02 | $4.92 | $11.52 | |
| P/B | 1.0x | 0.8x | 1.1x | 0.9x | 1.5x |
| EPS | -$2.02 | -$2.38 | -$2.74 | -$7.56 | |
| ROE | -47.70% | -69.24% | -45.57% | -49.83% | -18.28% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FBIOFortress Biotech, Inc. | $2.77 | 1.0x | 0.6x | — | 115.98% | $92.38M |
| ACHAccendra Health Inc | $1.21 | — | — | — | — | $93.05M |
| ICCCImmucell Corp | $9.94 | 142.0x | 2.9x | — | 2.57% | $90.28M |
| DWTXDogwood Therapeutics, Inc. | $2.65 |
About the company
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
- 74
- Watertown, United States
Company description provided by Yahoo Finance.